Respiratory Virus Infection Drugs Market (By Drug Type: Cough Suppressants, Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Nasal Decongestants, and Others; By Infection Type, By Route of Administration, By Mode of Purchase, By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030

Published Date : Jul 2021 | No. of Pages : 150+ Pages | Category : Healthcare

According to latest report, the global respiratory virus infection drugs market reached value at US$ 38.8 Bn in 2020 and predicted to hit around US$ 82.1 billion by 2030, expanding at a CAGR of 7.1% from 2021 to 2030.

The viral respiratory infection affects the upper and lower respiratory tract. The respiratory virus infection is commonly caused by respiratory syncytial viruses, rhinoviruses, parainfluenza viruses, and influenza viruses. The global respiratory virus infection drugs market is driven by investments by key players to develop advanced therapeutics. Moreover, increase in acceptance of combination therapy to boost success rate of respiratory treatment presents significant opportunities to market players. These factors drive the global market.

Rise in R&D Helps Address Low Solubility of Favipiravir in Aqueous Media

The respiratory virus infection drugs market is expected to surpass a value of US$ 82.1 Bn by the end of 2030. However, individuals are becoming increasingly aware about the disadvantages and side effects of influenza drugs, namely favipiravir and baloxavir. Pharma companies need to address low solubility of favipiravir in aqueous media, which may reduce its efficacy in vitro. This indicates that pharma companies need to increase their R&D activities to prevent adverse events of drugs.

Pharma companies are focusing on discoveries in influenza virus polymerase complex. It has been found that influenza viruses are severe human pathogens that pose as a persistent threat to public health. Hence, companies in the respiratory virus infection drugs market are capitalizing on this issue to increase their R&D in influenza virus polymerase complex.

Efficient Drug Delivery via Nanotechnology Offers Growth Prospects in Clinical Practice

Companies in the respiratory virus infection drugs market are increasing their focus in nanomaterials designed for antiviral drug delivery of adenovirus infection. This has become important, since respiratory virus infections have become a global health problem causing a significant amount of mortality and morbidity in individuals. Emerging drug resistance and constant viral replication have led to the demand for nanotechnology in antiviral therapies, as nanomaterials offer unique physic-chemical properties ideal for the treatment of adenovirus infection.

Different nanomaterials such as nanosheres, liposomes, nanoparticles, nanogels, and the likes hold promising potentials for efficacious drug administration in order to improve patient outcomes. Companies in the respiratory virus infection drugs market are innovating in nanosuspensions and nanoemulsions to enable drug delivery of unique antiviral agents with prospects in clinical practice.

AI-based Multi-program Approach Enables Development of Successful Candidates for Antibiotic Resistance

The COVID-19 pandemic has brought startups in the respiratory virus infection drugs market under great emphasis. For instance, Vir Biotechnology— a specialist in immune therapeutics, is leveraging the advantages of AI and ML in influenza drug development. It has been found that infectious diseases have increased resistance to antibiotics. Startups in the respiratory virus infection drugs market are capitalizing on this opportunity to integrate AI and ML in common cold and influenza drug development.

In order to broaden their revenue streams, the U.S.-based tech startups are working on solutions to address antibiotic resistance in certain strains of influenza A, SARS-CoV-2, and tuberculosis. They are adopting a multi-program and multi-platform approach to develop successful candidates in order to tackle antibiotic resistance. Manufacturers are innovating in antibody platforms and T cell platforms to isolate rare antibodies and use them to boost the immune system.

Report Highlights

In terms of drug type, the global respiratory virus infection drugs market has been classified into antibiotics, non-steroidal anti-inflammatory drugs (NSAIDS), cough suppressants, nasal decongestants, and others. Macrolides are a group of antibiotics considered promising treatment option for respiratory viral infections. This is likely to augment the segment.

Based on infection type, the global respiratory virus infection drugs market has been divided into respiratory syncytial virus (RSV) infection, influenza virus infection, parainfluenza virus infection, adenovirus infection, rhinovirus infection, and others. Adults with asthma, congestive heart failure, and COPD are at higher risk of suffering from respiratory syncytial virus infection. Hence, increase in the number of patients with these risk factors is projected to propel the segment.

In terms of route of administration, the global respiratory virus infection drugs market has been bifurcated into oral and parenteral. The preference of oral route due to better patient compliance, ease of administration, and versatility to accommodate various types of drug is anticipated to boost the growth of segment.

Based on mode of purchase, the global respiratory virus infection drugs market has been categorized into prescription-based drugs and over-the-counter drugs. Increase in awareness about the usage of antibiotics and standard guidelines for prescription antibiotics fuel the growth of the segment.

In terms of distribution channel, the global respiratory virus infection drugs market has been segregated into hospital pharmacies, drug stores, retail pharmacies, clinics, and others. Introduction of newer prescription products and availability of different dosage forms at hospital pharmacies are likely to drive the segment.

North America dominated the global respiratory virus infection drugs market in 2020, followed by Europe. North America accounted for a major share of the global respiratory virus infection drugs market in 2020. Presence of key players and focus on research & development are key factors projected to propel the respiratory virus infection drugs market in the region. 

The respiratory virus infection drugs market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. The increase in investment by key players is expected to augment the respiratory virus infection drugs market in the region.

Key Players

Key players in the global respiratory virus infection drugs market include GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, Cipla, Inc., CHIESI Farmaceutici S.p.A., and Orion Corporation.

Market Segmentation

By Drug Type

    • Antibiotics
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • Cough Suppressants
    • Nasal Decongestants
    • Others

By Infection Type

    • Respiratory Syncytial Virus (RSV) Infection
    • Influenza Virus Infection
    • Parainfluenza Virus Infection
    • Adenovirus Infection
    • Rhinovirus Infection
    • Others

By Route of Administration

    • Oral
    • Parenteral

By Mode of Purchase

    • Prescription-based Drugs
    • Over-the-counter Drugs

By Distribution Channel

    • Hospital Pharmacies
    • Drug Stores
    • Retail Pharmacies
    • Clinics
    • Others

By Region

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

This report focuses on respiratory virus infection drugs market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall respiratory virus infection drugs market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global respiratory virus infection drugs market.

The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.

In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).

The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Regional Analysis

The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.

The report provides in-depth segment analysis of the global respiratory virus infection drugs market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the respiratory virus infection drugs market.

The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.

In this study, the years considered to estimate the market size of respiratory virus infection drugs are as follows:

  • History Year: 2017-2019
  • Base Year: 2020
  • Forecast Year 2021 to 2030

Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.

The analysts have provided a comprehensive analysis of the competitive landscape of the global respiratory virus infection drugs market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.

  • Company Overview
  • Company Market Share/Positioning Analysis
  • Product Offerings
  • Financial Performance
  • Recent Initiatives
  • Key Strategies Adopted by Players
  • Vendor Landscape
  • List of Suppliers
  • List of Buyers

 

Research Methodology

The research methodology adopted by analysts for compiling the global respiratory virus infection drugs market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global respiratory virus infection drugs market.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2021) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Featured Research Reports

  • Featured Research Reports

    Clinical Trial Equipment & Ancillary Solutions Market (By Product: Sourcing, Supply/Logistics, Service, Others; By Phase: Phase I, Phase II, Phase III, Phase IV) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Dental Suction Systems Market (By Product: Wet Suction, Dry Suction; By End-use: Hospitals, Dental Offices) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Dental Caries Detectors Market (By Product: Laser Fluorescent Caries Detector, Fiber Optic Trans-illumination Caries Detector; By End-use: Hospitals, Dental Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Ophthalmic Perimeters Market (By Product: Static, Kinetic, Combination; By End-use: Hospital, Ophthalmic Clinic, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...
  • Featured Research Reports

    Investigational New Drug CDMO Market (By Product: Small Molecule, Large Molecule; By Service: Contract Development, Contract Manufacturing; By End-use: Pharmaceutical Companies, Biotech Companies, Others (Government, Research Institutes, Academic Institutes, etc.)) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

    Read more...